Sun Pharmaceutical Industries' Q3 FY 2025-26 Quarterly Results
- 01 Feb 2026
Result Summary
- Sun Pharmaceutical Industries Ltd reported a 7.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 13.8%.
- Its expenses for the quarter were up by 5.6% QoQ and 10.0% YoY.
- The net profit increased 8.2% QoQ and increased 16.1% YoY.
- The earnings per share (EPS) of Sun Pharmaceutical Industries Ltd stood at 14 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 16099.38 | 14948.23 | 14141.08 | 7.7% | 13.8% |
Total Expenses | 11382.74 | 10780.62 | 10348.51 | 5.6% | 10.0% |
Profit Before Tax | 4548.73 | 4167.61 | 3476.40 | 9.1% | 30.8% |
Tax | 1147.64 | 1030.52 | 558.86 | 11.4% | 105.4% |
Profit After Tax | 3381.17 | 3124.95 | 2912.98 | 8.2% | 16.1% |
Earnings Per Share | 14.00 | 13.00 | 12.10 | 7.7% | 15.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sun Pharmaceutical Industries Ltd, commonly known as Sun Pharma, is a leading pharmaceutical company in India. It is one of the largest specialty generic pharmaceutical companies in the world, providing high-quality, affordable medicines trusted by healthcare professionals and patients in over 100 countries worldwide. The company manufactures and sells complex generics, branded generics, specialty, active pharmaceutical ingredients (APIs), and intermediates in a variety of therapeutic segments. Sun Pharma has a robust pipeline of products at various stages of development. As of the latest data, it continues to focus on expanding its presence in key markets through strategic acquisitions and organic growth. Specific recent developments or major events were not available in the provided data.
Revenue
During Q3FY26, Sun Pharmaceutical Industries Ltd reported a Total Income of ₹16,099.38 crores, marking a 7.7% increase from the previous quarter (Q2FY26) where the Total Income was ₹14,948.23 crores. Compared to the same quarter in the previous year (Q3FY25), there was a 13.8% increase from ₹14,141.08 crores. This growth in revenue may be indicative of the company's strong market position and potential successful execution of its business strategies. The YoY and QoQ increases are notable and reflect the company's consistent performance in revenue generation over this period.
Profitability
For Q3FY26, Sun Pharma's Profit Before Tax (PBT) was ₹4,548.73 crores, depicting a 9.1% increase over the previous quarter (Q2FY26) where PBT was ₹4,167.61 crores. Year-over-year, there was a significant increase of 30.8% from Q3FY25 when the PBT was ₹3,476.40 crores. The Tax expense for Q3FY26 was ₹1,147.64 crores, up 11.4% from Q2FY26 and 105.4% from Q3FY25. Consequently, the Profit After Tax (PAT) for Q3FY26 stood at ₹3,381.17 crores, which is an 8.2% increase QoQ and a 16.1% increase YoY from ₹2,912.98 crores in Q3FY25. Earnings Per Share (EPS) for Q3FY26 was ₹14.00, reflecting a 7.7% increase from the previous quarter and a 15.7% increase from the same quarter last year.
Operating Metrics
The company recorded Total Expenses of ₹11,382.74 crores for Q3FY26, which is a 5.6% increase from Q2FY26's expenses of ₹10,780.62 crores and a 10.0% increase from Q3FY25's expenses of ₹10,348.51 crores. These metrics suggest a controlled increase in expenses relative to income growth, contributing to the company's overall profitability. The figures reflect Sun Pharma's operational scale and its ability to manage costs while continuing to grow its income. The consistent increase in both revenues and expenses suggests an expansion in operational activities during this period.